Stockscreener 앱 받기
1.9464
1.52%
-0.0336
전일 마감가:
$1.98
열려 있는:
$1.98
하루 거래량:
91,712
Relative Volume:
0.09
시가총액:
$5.46M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.52%
1개월 성능:
-66.49%
6개월 성능:
-84.86%
1년 성능:
+0.00%
1일 변동 폭
$1.94
$2.0442
1주일 범위
$1.90
$3.18
52주 변동 폭
$1.76
$1,095.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
명칭
Cero Therapeutics Holdings Inc
전화
650-407-2376
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
CERO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
1.94 | 5.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.70 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
706.55 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.85 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.51 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.54 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cero Therapeutics Holdings Inc 주식(CERO)의 최신 뉴스
Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) - Defense World
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Down 97.9% in January - Defense World
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
CERO Therapeutics secures NASDAQ compliance extension - MSN
CERO stock touches 52-week low at $2.83 amid steep annual decline - Investing.com Nigeria
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer - Marketscreener.com
CERo Therapeutics : Amendments to Bylaws Form 8 K - Marketscreener.com
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - Marketscreener.com
CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer - Marketscreener.com
CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter - Marketscreener.com
CERo Therapeutics Holdings, Inc. Appoints Chris Ehrlich CEO - Marketscreener.com
CERo Therapeutics Holdings, Inc. Appoints Kristen Pierce as Chief Development Officer - Marketscreener.com
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
CERo Therapeutics Holdings, Inc. Announces CEO Changes - Marketscreener.com
CERo Therapeutics (NASDAQ:CERO) Hits New 12-Month LowTime to Sell? - MarketBeat
CERo Therapeutics to implement reverse stock split - MSN
Stock market news: SPI Energy saw rise of 276.74% while Hoth Therapeutics surged by 186.73% during mid day trading - Business Upturn
Cero Therapeutics to effect 1-for-100 reverse stock split - Yahoo Finance
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - The Manila Times
CERo Therapeutics Announces 1:100 Reverse Stock Split to Avoid Nasdaq Delisting - StockTitan
CERO stock plunges to 52-week low, touches $0.05 - Investing.com
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Cero Therapeutics holdings sees $400,456 in stock sales by YK Bioventures - Investing.com Australia
Cero Therapeutics sees $383,369 in stock sales by YK Bioventures - Investing.com Australia
CERo Therapeutics appoints Chris Ehrlich CEO - MSN
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewswire
CERo Therapeutics Names Chris Ehrlich Permanent CEO, Advances Novel Cancer Treatment Pipeline - StockTitan
Cero therapeutics investor Sloan Stuart sells $55,538 in stock By Investing.com - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN
CERo Therapeutics Holdings Inc. (CERO) reports earnings - Quartzy
Selling Your CERo Therapeutics Holdings Inc (CERO) Stock? Here’s What You Need To Know - Stocks Register
Cero Therapeutics holdings sees $325,000 stock sale by YK Bioventures - Investing.com India
FDA clears CERo's new AML drug for phase 1 trials - Investing.com
FDA clears CERo's new AML drug for phase 1 trials By Investing.com - Investing.com UK
CERo Therapeutics, Inc. Receives FDA Clearance of - GlobeNewswire
CERo Therapeutics Secures FDA Clearance for Novel AML Treatment Clinical Trial | CERO Stock News - StockTitan
Nasdaq Tumbles Over 200 Points; Alibaba Posts Upbeat SalesArena Group Holdings (AMEX:AREN) - Benzinga
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Nuclear stock Oklo jumps on data center partnership - Investing.com
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
CERo Therapeutics Holdings, Inc. (CERO): 173% Stock Surge Driven by Promising Preclinical Data for Lead Compound CER-1236 - BP Journal
Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga
Cero Therapeutics Holdings Inc (CERO) 재무 분석
Cero Therapeutics Holdings Inc (CERO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.72%
3.18%
자본화:
|
볼륨(24시간):